A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib

A Study to Evaluate Effectiveness of Upadacitinib in Moderate to Severe AD With Prurigo Nodularis in the Real World in Japan

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05451316

Acronym

ADMIRE

Enrollment

Registered

2022-07-11

Start date

2022-12-08

Completion date

2024-11-02

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

Prurigo Nodularis, Prurigo-type AD, Skin, Dermatology, Upadacitinib, ADMIRE, RINVOQ

Brief summary

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by intense, persistent itchy skin and sometimes pain with burning. In this study, the effectiveness of upadacitinib (UPA) will be assessed in participants with prurigo-type AD in a real world (RW) setting in Japan. UPA is an approved drug for the treatment of AD. Adults and adolescents who have been diagnosed with prurigo-type AD and prescribed UPA according to the label and practice in Japan will be enrolled in this observational study. The doctor's decision to prescribe UPA will be made prior to and independently of study participation. Approximately 200 participants will be enrolled in the study at 10 sites in Japan. Participants will receive extended-release oral tablets of UPA once-daily for 48 weeks. There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Physician confirmed diagnosis of moderate to severe atopic dermatitis (AD) at baseline * AD symptom onset \> 1 year prior to baseline * Initiation of UPA treatment for AD is indicated and prescribed per the label in Japan * Worst Pruritus Numerical Rating Scale (WP-NRS) ≥ 4 at baseline * Presence of palpable prurigo nodules at baseline

Exclusion criteria

* Prior treatment with UPA * Contraindications to UPA * Chronic pruritus resulting from another condition (e.g., neuropathic disorders) than AD, prurigo nodularis (PN) * PN caused by medication, metal allergy, infection, insect bite * Current participation in interventional research

Design outcomes

Primary

Measure	Time frame	Description
Percentage of participants achieving Worst Pruritus Numerical Rating Scale (WP-NRS) reduction ≥ 4.	Up to Week 12	WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours in patients with moderate to severe AD, based on the following question: "On a scale 0 to 10, with 0 being 'no itch' and 10 being 'worst imaginable itch', how would you rate your itch at its worst during the past 24 hours?"

Countries

Japan

Contacts

STUDY_DIRECTORABBVIE INC.

AbbVie

Outcome results